Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05878795 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Written Exposure Therapy for Suicide Prevention

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates: Jun 2026 to Sep 2027v14
  2. Minor Re-verified, no change to tracked fieldsv13
  3. Notable Primary and study completion dates: Jun 2025 to Jun 2026
    • Eligibility criteria shortened, about 4 words
    v12
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 2024 to Aug 20, 2024
    • Site details revised
    v11
  5. Minor Start date: Jul 2024 to Aug 2024v10
Show 8 earlier versionsHide 8 earlier versions
  1. Notable Start date: May 2024 to Jul 2024
    • Primary and study completion dates: Dec 2024 to Jun 2025
    v9
  2. Notable Start date: Mar 2024 to May 2024v8
  3. Notable Start date: Jan 2024 to Mar 2024
    • Primary and study completion dates: Sep 2024 to Dec 2024
    v7
  4. Notable Start date: Oct 2023 to Jan 2024v6
  5. Minor Primary and study completion dates: Jun 2024 to Sep 2024
    • Start date: Sep 2023 to Oct 2023
    v5
  6. Minor Start date: Aug 2023 to Sep 2023v4
  7. Minor Start date: Jul 2023 to Aug 2023v3
  8. Minor Study title shortened, about 4 wordsv2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Military service members admitted to inpatient psychiatry for self-injurious thoughts and behaviors (SITBs) represent an at-risk group for continued SITBs and rehospitalizations in the post-discharge period. However, there is an absence of evidence-based interventions designed to be delivered on inpatient psychiatric units to reduce the risk of post-discharge SITBs. To address this gap, the investigator's research group developed Written Exposure Therapy for Suicide Prevention (WET-SP), a brief, scalable, suicide-specific psychotherapy based on the written disclosure paradigm. Written disclosure, in which an individual writes about a personally stressful experience and the related thoughts and feelings, yields improvements across physical and psychiatric domains. Pilot data suggest that written exposure also yields reductions in SITBs. Yet, no study has adapted the written exposure paradigm specifically to target the amelioration of distress associated with suicidal crises and examined whether implementing WET-SP reduces the risk of subsequent SITBs and suicide-related hospitalizations. The primary objective of this randomized controlled trial (RCT) is to evaluate the efficacy of WET-SP, in reducing the incidence and severity of SITBs in active duty military service members following a psychiatric hospitalization due to suicidal ideation, suicide plans, or a suicide attempt. Secondary objectives are to evaluate a potential mechanism of change (i.e., decreases in thwarted belongingness \[cf. social disconnectedness\]) and moderator of outcomes (i.e., arc of narrative \[cf. linguistical parameters of the written narratives generated during treatment\]). Participants randomized to WET-SP + TAU will receive five sessions of WET-SP delivered by the study team during their psychiatric hospitalization plus treatment-as-usual (TAU). Participants randomized to TAU will receive daily contact and patient-centered care delivered by the acute psychiatric inpatient unit provider team (e.g., psychiatrists, therapists, case managers). TAU includes psychiatric assessment, initial stabilization, nurse case management, medication management, treatment of medical comorbidities, group and individual therapy, and discharge planning. Outcome assessments will be administered at pretreatment, posttreatment, and 10-, 20-, and 30-week follow-ups.
Trial Details
NCT Number NCT05878795
Lead Sponsor Boston University
Collaborators: United States Department of Defense, The University of Texas Health Science Center at San Antonio, University of Colorado, Denver
Conditions
(from sponsor)
Suicide, Attempted, Suicide Threat
Related terms Behavior, Suicide, Attempted
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov